Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)

NCT02156843 is registered in ClinicalTrials.gov with NephroGenex, Inc. as lead sponsor.

NCT NCT02156843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02156843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)
Lead sponsor
NephroGenex, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2014
Completion date
March 31, 2018
Enrollment
328 (actual)
Sites
137

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease, diabetic nephropathy